Who are Korro Bio, Inc.'s main suppliers?

Korro Bio, Inc. (KRRO) key suppliers include: GENEVANT. View the full supplier network at chainsifter.com/chain/KRRO.

Who are Korro Bio, Inc.'s major customers?

Korro Bio, Inc. (KRRO) key customers include: ADAR1-CAPITAL-MANAGEMENT, AFFINITY-ASSET-ADVISORS, BALYASNY-ASSET-MANAGEMENT, DRIEHAUS-CAPITAL-MANAGEMENT, KALEHUA-CAPITAL and 5 more. View the full customer network at chainsifter.com/chain/KRRO.

What sector is Korro Bio, Inc. in?

Korro Bio, Inc. (KRRO) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

KRRO Supply Chain: Korro Bio, Inc. Suppliers & Customers

1Suppliers

10Customers

2Debt Items

20Related Chains

Korro Bio, Inc. Suppliers

Ticker	Name	Confidence	Evidence
GENEVANT	GENEVANT	92%	For example, in March 2023, we entered into a collaboration and license agreement with Genevant, a well established leader in the LNP space, to provide access to clinically validated LNP technology t…

Korro Bio, Inc. Customers

Ticker	Name	Confidence	Evidence
ADAR1-CAPITAL-MANAGEMENT	ADAR1-CAPITAL-MANAGEMENT	92%	with participation from new and existing investors, including ADAR1 Capital Management
AFFINITY-ASSET-ADVISORS	AFFINITY-ASSET-ADVISORS	92%	with participation from new and existing investors, including Affinity Asset Advisors
BALYASNY-ASSET-MANAGEMENT	BALYASNY-ASSET-MANAGEMENT	92%	with participation from new and existing investors, including Balyasny Asset Management
DRIEHAUS-CAPITAL-MANAGEMENT	DRIEHAUS-CAPITAL-MANAGEMENT	92%	with participation from new and existing investors, including Driehaus Capital Management
KALEHUA-CAPITAL	KALEHUA-CAPITAL	92%	with participation from new and existing investors, including Kalehua Capital
LYNX1-CAPITAL-MANAGEMENT	LYNX1-CAPITAL-MANAGEMENT	92%	with participation from new and existing investors, including Lynx1 Capital Management
NANTAHALA-CAPITAL	NANTAHALA-CAPITAL	92%	with participation from new and existing investors, including Nantahala Capital
NEW-ENTERPRISE-ASSOCIATES	NEW-ENTERPRISE-ASSOCIATES	92%	with participation from new and existing investors, including New Enterprise Associates
NOVO-NORDISK	NOVO-NORDISK	92%	The Company assessed this arrangement in accordance with ASC Topic 606, Revenue from Contracts with Customers, and concluded that the contract counterparty, Novo Nordisk, is a customer.
VENROCK-HEALTHCARE-CAPITAL-PARTNERS	VENROCK-HEALTHCARE-CAPITAL-PARTNERS	92%	The private placement was led by Venrock Healthcare Capital Partners, with participation from new and existing investors

Korro Bio, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
KRRO-DEBT-10571	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2018-12-31.
KRRO-DEBT	Debt stack $42.9M	90%	Market cache reports total debt of $42.9M.

Korro Bio, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Korro Bio, Inc..

Korro Bio, Inc. Ownership

Holder	Name	Confidence	Evidence
KRRO-OWNER-LYNX1-CAPITAL-MANAGEMENT-LP	Lynx1 Capital Management LP	90%	13F overlay lists Lynx1 Capital Management LP as top holder; 100 tracked holders.

Korro Bio, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
CRBP	Corbus Pharmaceuticals Holdings, Inc.	100.00	2
CANF	Can-Fite BioPharma Ltd.	100.00	2
BEAM	Beam Therapeutics Inc.	100.00	2
SDGR	Schrödinger, Inc.	100.00	2
ALNY	Alnylam Pharmaceuticals, Inc.	100.00	2
GRFS	Grifols, S.A.	100.00	2
EVAX	Evaxion A/S	100.00	2
HIMS	Hims & Hers Health, Inc.	100.00	2
IPHA	Innate Pharma S.A.	100.00	2
KRYS	Krystal Biotech, Inc.	100.00	2
NONOF	Novo Nordisk A/S	100.00	2
ASND	Ascendis Pharma A/S	100.00	2
SNYNF	Sanofi	100.00	2
LLY	Eli Lilly and Company	100.00	2
NVSEF	Novartis AG	100.00	2
WVE	Wave Life Sciences Ltd.	100.00	2
MDGL	Madrigal Pharmaceuticals, Inc.	50.00	2
IXHL	Incannex Healthcare Inc.	50.00	2
LCTX	Lineage Cell Therapeutics, Inc.	50.00	2
GYRE	Gyre Therapeutics, Inc.	50.00	2

Korro Bio, Inc. Supply Chain